Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
EBV indices (infectious mononucleosis history and anti‐EBNA IgG titer), lower 25(OH)D, low sun exposure, and HLA‐DRB1*1501 risk variant were individually and jointly associated with MS risk.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Case-control study.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
This was a Swedish MS case: control study, matched on age, sex, and ethnicity.
Source: Methods.
At the EIMS study clinic, participants were queried for a range of environmental factors, including IM history and sun exposure behaviors using standardized questionnaires.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA‐DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset
Case-control study · Annals of Neurology · 2025
Original publication title
Epstein: Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA‐DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset
© 2025 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Multiple sclerosis (MS) onset risk factors include Epstein: Barr virus (EBV) indices (including host response), lower serum 25‐vitamin D (25(OH)D) levels, low sun exposure, and HLA‐DRB1*1501. The underlying molecular mechanisms are unclear. Here, we examined mediation through differential DNA methylation (DNAm) to better understand possible epigenetic programming.
Source: ObjectivesAbstract: What methods does the paper describe?
Two case‐control studies (Ausimmune Study, Australia = 206 cases + 348 controls; and Epidemiologic Investigations of MS [EIMS], Sweden = 140 cases + 139 controls). DNAm was measured using Illumina arrays. Dimension‐reduction methods generated MS‐associated DNAm modules. Pathway enrichment analyses were used to describe DNAm modules’ system‐level biological characteristics. Individual and joint associations with MS risk were assessed using logistic regression. DNAm module mediation of risk factor‐outcome associations were assessed using mediation analysis. A range of temporality analyses were used.
Source: MethodsAbstract: Results
EBV indices (infectious mononucleosis history and anti‐EBNA IgG titer), lower 25(OH)D, low sun exposure, and HLA‐DRB1*1501 risk variant were individually and jointly associated with MS risk. In each study, 2 DNAm modules were found which mediated multiple exposure‐MS associations. Proportions mediated ranged from 21 to 47% in Ausimmune and 25 to 53% in EIMS. Results were robust to sensitivity analyses. Top‐ranked genomewide association study (GWAS) MS risk‐associated genes were over‐represented in both Ausimmune DNAm modules, A1 3.5‐fold (p = 0.004) and A2 3‐fold (p = 0.015).
Reactome pathways enriched for DNAm had cross‐study overlap: 45% of pathways enriched in Ausimmune DNAm modules were also enriched in EIMS (4.82‐fold, p < 0.001).
Source: ResultsAbstract: Interpretation
EBV, lower vitamin D, low sun exposure, and HLA‐DRB1*1501 risk variant act in concert and through common epigenetic pathways to impact MS onset risk. ANN NEUROL 2026;99:341 to 355
Source: InterpretationAuthors’ abstract
Objectives
Multiple sclerosis (MS) onset risk factors include Epstein: Barr virus (EBV) indices (including host response), lower serum 25‐vitamin D (25(OH)D) levels, low sun exposure, and HLA‐DRB1*1501. The underlying molecular mechanisms are unclear. Here, we examined mediation through differential DNA methylation (DNAm) to better understand possible epigenetic programming.
Methods
Two case‐control studies (Ausimmune Study, Australia = 206 cases + 348 controls; and Epidemiologic Investigations of MS [EIMS], Sweden = 140 cases + 139 controls). DNAm was measured using Illumina arrays. Dimension‐reduction methods generated MS‐associated DNAm modules. Pathway enrichment analyses were used to describe DNAm modules’ system‐level biological characteristics. Individual and joint associations with MS risk were assessed using logistic regression. DNAm module mediation of risk factor‐outcome associations were assessed using mediation analysis. A range of temporality analyses were used.
Results
EBV indices (infectious mononucleosis history and anti‐EBNA IgG titer), lower 25(OH)D, low sun exposure, and HLA‐DRB1*1501 risk variant were individually and jointly associated with MS risk. In each study, 2 DNAm modules were found which mediated multiple exposure‐MS associations. Proportions mediated ranged from 21 to 47% in Ausimmune and 25 to 53% in EIMS. Results were robust to sensitivity analyses. Top‐ranked genomewide association study (GWAS) MS risk‐associated genes were over‐represented in both Ausimmune DNAm modules, A1 3.5‐fold (p = 0.004) and A2 3‐fold (p = 0.015).
Reactome pathways enriched for DNAm had cross‐study overlap: 45% of pathways enriched in Ausimmune DNAm modules were also enriched in EIMS (4.82‐fold, p < 0.001).
Interpretation
EBV, lower vitamin D, low sun exposure, and HLA‐DRB1*1501 risk variant act in concert and through common epigenetic pathways to impact MS onset risk. ANN NEUROL 2026;99:341 to 355
Publication and source details
Original title: Epstein: Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA‐DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset
Steve Simpson‐Yap; Ellen Morwitch; Samuel A. Tanner; Sarah M. Thomson; Alex Eisner; Rod A. Lea; Trevor J. Kilpatrick; Jeannette Lechner‐Scott; Rodney J. Scott; Alexandre Xavier; Vicki E. Maltby; Robyn M. Lucas; Bruce V. Taylor; Brett A. Lidbury; Simon A. Broadley; Ingrid van der Mei; Mehari Woldemariam Merid; Boris Novakovic; Richard Saffery; Anna Karin Hedström; Pernilla Stridh; Tomas Olsson; Maja Jagodic; Lars Alfredsson; Anne‐Louise Ponsonby; for the Ausimmune Investigator GroupChapmanCaronMBBS, FRACPKilpatrickTrevorMBBS, PhD, FRACPLucasRobynMB, MPH, PhD, FFPHMMcMichaelTonyAO, MBBS, PhDPonsonbyAnne‐LouiseBMedSci, MBBS, PhD, FAFPHM, FRACPTaylorBruceBMedSci, MMS, MD, FRACPvan der MeiIngridMSci(Env Health), MSci(Human Movement), PhDWilliamsDavidMBBS, PhD, FRACP; Alan Coulthard BMedSci, MBBS, FRANZCR, FRCR, FRCS(Ed); Keith Dear MA, MSc (Biometry), PhD; Terry Dwyer MBBS(Hons), MPH, MD; Patricia Valery MPH, PhD
Annals of Neurology · 2025
* Address correspondence to Prof Ponsonby, The Florey Institute of Neuroscience and Mental Health, 30 Royal Parade, Parkville VIC 3052, Australia. E‐mail: annelouise.ponsonby@florey.edu.au© 2025 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Swedish Brain Foundation (Hjärnfonden)10.13039/501100003792 Margaretha af Ugglas Stiftelse National Health and Medical Research Council10.13039/501100000925 Knut och Alice Wallenbergs Stiftelse10.13039/501100004063 Stockholm läns landsting, ALF Project10.13039/501100011727 Multiple Sclerosis Australia10.13039/501100000924 National Multiple Sclerosis Society10.13039/100000890 Forskningsrådet om Hälsa, Arbetsliv och Välfärd10.13039/501100006636 Medical Research Future Fund10.13039/501100025520
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:16:35.661567+00:00
DOI: 10.1002/ana.78043 · PMC12894492